Review anchor
Maternal embryonic leucine zipper kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
Evidence Snapshot
Maternal embryonic leucine zipper kinase
CHEMBL4578
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Maternal embryonic leucine zipper kinase as ChEMBL target CHEMBL4578, mapped to UniProt Q14680. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4578
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-12
www.ebi.ac.uk
UniProt accession
Q14680
Maternal embryonic leucine zipper kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-12
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Maternal embryonic leucine zipper kinase matters
Maternal embryonic leucine zipper kinase is reviewed as Maternal embryonic leucine zipper kinase (UniProt Q14680); the current evidence base includes 12 approved drugs, 2667 compounds, and 380 assays, with lead potency reaching pChEMBL 9.8.
Protein context
Maternal embryonic leucine zipper kinase
Maternal embryonic leucine zipper kinase Sequence length is 651 aa.
Review this target as Maternal embryonic leucine zipper kinase, mapped to UniProt Q14680. Sequence length is 651 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q14680
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 12 approved drugs, 2667 compounds, and 380 assays for this target. The dominant activity type is IC50. CHEMBL4077934 is the current potency anchor at pChEMBL 9.8.
Use CHEMBL4077934 as the tractability anchor when discussing potency (pChEMBL 9.8).
Activity source · ChEMBL 36 via Core Engine
12 approved
pChEMBL 9.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Maternal embryonic leucine zipper kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q14680, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2667
Total Compounds
380
Total Assays
12
Approved Drugs
IC50: 991.0, KI: 590.0, EC50: 2.0, KD: 370.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4077934
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL3688335
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL3688376
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL3824328
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL1980995
|
9.5 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header